Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pacritinib Capsule vs Solution in Healthy Subjects
NCT02808455Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pacritinib in myelofibrosis (MF) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration and 2 more. Started Jan 2015; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02808455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808455.